PT Prodia Diagnostic Line Tbk (PRDL) has set an ambitious target to maintain its business growth momentum in 2026. The issuer in the medical diagnostic equipment manufacturing sector is optimistic about recording double-digit revenue and net profit growth, following positive performance recorded in the previous year.
President Director of Prodia Diagnostic Line, Cristina Sandjaja, revealed that the company's main strategy will focus on portfolio enrichment through the launch of new diagnostic products not yet available in the domestic market. This initiative is planned to roll out starting in the second semester of 2026 to strengthen the company's contribution to the national health system.
In addition to product innovation, PRDL is evaluating market reach expansion. Currently, the company is supported by 70 distributors serving 370 regencies and cities across Indonesia. However, management sees significant potential in around 200 other unreached areas, which will become targets for the expansion of the company's distribution network in the near future.
As market reliance on the government sector accounts for over 60% of its customer base, PRDL is leveraging the momentum of increased national health budgets and government mass screening programs. The company also ensures operational readiness in facing economic dynamics, including mitigating exchange rate fluctuations through strategic raw material inventory management.
The funds raised from the Initial Public Offering (IPO) corporate action will serve as the main catalyst in this plan. A total of 62% of the funds will be allocated to strengthen capital structure through the repayment of productive loans, while the remainder will be allocated for capital expenditure on production machinery and working capital to support the future operational sustainability of the company.
